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Abstract—This work proposes a unified framework to leverage
biological information in network propagation-based gene prior-
itization algorithms. Preliminary results on breast cancer data
show significant improvements over state-of-the-art baselines,
such as the prioritization of genes that are not identified as
potential candidates by interactome-based algorithms, but that
appear to be involved in/or potentially related to breast cancer,
according to a functional analysis based on recent literature.
Index Terms—Gene prioritization, interactome, PPI network,
flow propagation algorithms, Gene Ontology.
I. INTRODUCTION AND RELATED WORK
Today, big data, genomics, and quantitative in silico method-
ologies integration, have the potential to push forward the
frontiers of medicine in an unprecedented way [8], [17].
Clinicians, diagnosticians and therapists have long striven to
determine single molecular traits that lead to diseases. What
they had in mind was the idea that a single golden bullet
drug might provide a cure. Unfortunately, individual diseases
rarely share the same mutations. This reductionist approach
largely ignores the essential complexity of human biology.
Indeed, a large body of evidence that is now emerging from
new genomic technologies, points out directly to the cause
of disease as perturbations within the interactome, i.e. the
comprehensive network map of molecular components and
their interactions [8].
As a matter of fact, a growing body of knowledge reveals
the association between groups of interacting proteins and dis-
ease within the so-called human interactome, representing the
cellular network of all physical molecular interactions [6]. Pre-
cisely, the human interactome is composed of direct physical,
regulatory (transcription factors binding), binary, metabolic
enzyme-coupled, protein complexes and kinase/substrate in-
teractions. Such network is largely incomplete as well as the
connections between genes and disease. Currently, more than
140,000 interactions between more than 13,000 proteins are
known (see e.g. [17], [21]. The interactome-based network
medicine approach [6] has proved to be very effective in the
study of many diseases, e.g. by identifying putative biomarkers
and subtypes to provide a rational approach to drug targeting
[6], [26].
“Disease proteins” are the product of genes whose mutations
have a causal effect on the respective phenotype. In other
words, such proteins work together in a network that gives rise
to a cellular function and its disruption ends up in a specific
disease phenotype. Disease proteins may provide targets for
cancer therapy such as, for example, imatinib which targets
the BCR-ABL fusion or gefitinib which binds and inhibits
EGFR [26]. However, the big picture is far more complicated,
since a large variety of factors affect the effectiveness of
a given drug for a specific patient. For example, targeted
inhibition of BRAF V600E in patients harboring this mutation,
is very effective in melanoma, but not in colorectal cancer
[26]. Improvement of precision therapy needs new approaches
able to capture information about molecular mechanisms by
characterizing disease proteins causing the disruption of tumor
driving pathways.
A key property of the underlying molecular network of
interactions is that disease proteins are not found to be
uniformly scattered across the interactome, but they tend to
interact with one another confined in one or several subgraphs
called disease modules [23]. In fact, disease proteins are prone
to participate in common biological activities such as, for
example, genome maintenance, cell differentiation or growth
signaling, which are the most relevant pathways in carcino-
genesis [26]. Consequently, the module property also reflects
the biological feature that disease proteins are often localized
on specific biological compartments (pathway, cellular space,
or tissue).
These considerations directly point towards the possibility
that, whenever a disease module sub-network is found, other
disease-related parts are likely to be identified in their topo-
logical neighborhood [6]. However, notwithstanding a strong
community commitment to find new protein interactions and
relevant mutations for disease characterization, the list is
largely incomplete. Moreover, identification of specific disease
genes is often impaired by gene pleiotropy, by the multi-genic
feature of many diseases, by the influence of a plethora of
environmental agents, and by genome variability [7].
The need for new disease genes (or disease proteins) as
putative candidates for diagnosis, treatment or drug targeting,
motivated the development of a number of algorithms for
predicting disease genes and modules [16]. The key question
is whether it is possible to find a way to fully characterize
such genes (with respect to non-disease genes) and find an
algorithm able to capture such features. From a network
perspective, the goal is to find correlations between disease
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gene location on the interactome and the network topology. In
other words, one hypothesizes that disease genes are embedded
within modules in ways that are amenable to some topological
feature descriptor. The recent [23] evidence-based biological
observation that disease genes are not randomly positioned in
the interactome has opened new possibilities for developing
algorithms for disease gene predictions.
Two groups of methodologies have emerged in the last
decade as the most promising ones: network propagation [11]
and modules-based [6], [16] algorithms. Network propagation
(or diffusion-based) algorithms rely on the assumption that
the information contained in the initial (known) set of disease
genes, flows through the network through nearby proteins. By
contrast, module-based algorithms rely on the hypothesis that
all cellular components that belong to the same topological,
functional or disease module have a high likelihood of being
involved in the same disease.
From the above discussion, it is clear that prioritizing
candidate disease genes using the interactome, i.e. the network
of physical protein interactions, and mutational data (known
disease gene or seeds), is still a largely open problem. A
reliable prioritization (or ranking) of new predicted disease
genes is very important from a biological viewpoint, since it
provides valuable information of a putative specific activity of
a gene in the development of a disease. Simply put, the smaller
its rank position, the more likely a gene is to be a ”true”
disease one. This allows providing experimenters/clinicians
with an ordered list of potentially interesting genes for further
scrutiny, possibly speeding the complex and costly task of
identifying the most promising candidates.
Our contribution. In this work, we provide a unified
framework to leverage biological information in network
propagation-based gene prioritization algorithms. This brings
to significant improvements over state-of-the-art algorithms.
In more detail, we modify a well-known random walk-based,
flow propagation algorithm [20], modifying the dynamics of
flow propagation according to the functional relevance of
nodes for the disease under consideration. We considered the
same diseases as [16] and multiple biological data sources. In
the remainder however, for the sake of space and for clarity
of exposition, we focus on breast cancer as a use case and
we adopt Gene Ontology Annotations - biological process [10]
(GO in the remainder) as added biological information.
In the output ranking of the algorithm we almost double the
number of known disease genes in the first 50 positions with
respect to state of the art baselines, in particular DIAMOnD
[16] and Random Walk with Restart [20]. Moreover, some very
promising candidates are prioritized by our algorithm but not
by baselines. Of these, some were only recently associated to
breast cancer, while others appear to be potentially related to
the disease according to a functional analysis based on recent
literature, as discussed in Section II.
Roadmap. The rest of this paper is organized as follows.
Section II gives an overview of our findings and their potential
biological relevance. Section III provides background about
the baselines we considered, a more detailed account of
our approach and of the experimental setting. Due to space
limitations, it was only possible to include the most signif-
icant results and a concise report of experimental evidence
supporting the design choices we made.
II. RESULTS AND DISCUSSION
In this section, we present the main findings of our work.
In particular, we discuss the benefits of leveraging both bio-
logical and interactome information within gene prioritization
algorithms. To this purpose, we compared state of the art
prioritization algorithms that only rely on analysis of the
interactome, namely DIAMOnD [16] and Random Walk with
Restart [20], with two heuristics we propose: i) Biological
Node Relevance (BNR) only leverages biological information
(e.g., annotations) to prioritize genes; ii) Biological Random
Walk (BRW) is a random walk-based heuristic that, differently
from [20], also leverages biological information to bias the
random walk toward genes that are functionally closer to
known disease genes according to current literature.
BRW builds on the hypothesis that integrating different bi-
ological information sources may better reflect the complexity
of protein interactions in a cell’s process. In light of this in-
sight, our algorithm integrates information on pairwise protein
interaction reflected in the Protein-Protein Interaction network
(PPI) [6] with other biological data in a unified framework.
Our approach is to some extent agnostic to the particular
biological data source, as long as it affords a principled notion
of similarity between proteins. So for example, while we focus
on gene annotation data in this paper, the same approach
can be adopted to integrate different sources of biological
information, e.g. miRNA targets or pathway annotation data.
A. The role of biological information
We began by investigating the potential role of high-quality,
biological information (gene annotations in this case) in pri-
oritizing new candidates genes. To this purpose, we designed
a very simple heuristic that ranks genes of the PPI network
according to the degree of their co-occurrence in biological
processes, completely disregarding mutual interaction proper-
ties encoded by the PPI itself. Our Biological Node Relevance
heuristic (BNR in the remainder) prioritizes genes only on
the basis of their functional similarity with a seed set of
known disease genes, with similarity measured on the basis
of annotation data from the Gene Ontology database [10]
according to well-established similarity indices adopted in
Data Science. While details are provided in Section III, a high-
level description of the BNR is given in the paragraphs that
follow.
Given a seed set S0 of known disease genes, BNR ranks new
candidate genes according to the following steps:
1) We first compute the set of statistically significant anno-
tations for genes belonging to the seed set S0. We call
this the enriched set of annotations for the disease.
2) BNR then ranks each node i according to its
biological relevance BNR(i), namely, the extent of the
Fig. 1. PPI single experiment result. The Figure shows: the splitting of the known disease genes, i.e. train (seed) and test (validation) nodes, the retrieved
nodes by the different algorithms and the nodes’ names that have been highly ranked by the BRW. The size of train and test nodes is proportional to the
BNR, indeed node FGF10 has a very high score, inducing a high ranking despite has only one connection. Interestingly, BRW finds nodes retrieved by RWR
and DIAMOnD algorithms. Furthermore, the names of other highly ranked nodes by the BRW that aren’t present in the test set are shown, and they seem to
be promising candidate as breast cancer related genes, such as RAD50 [18], XRCC2 [27].
overlap between the enriched set and the set of gene’s
annotations.
Whilst it is reasonable to expect that curated, high-quality
annotations are likely to contain information that can be
leveraged to the purpose of gene prioritization, we observed
that BNR outperforms state of the art topology and flow-
based prioritization heuristics, in particular DIAMOnD [16]
and the well-established diffusion method based on random
walks with restart [20]. In particular, as shown in Figure 5,
BNR consistently recovers a larger fraction of known disease
genes among its top-k ranking candidates. This result suggests
that biological annotations (and, hopefully, other curated data)
contain rich information, which is not implicit in PPI networks
and thus cannot be leveraged by standard topology or flow-
based methods.
B. A unified framework
The Biological Random Walk (BRW in the remainder)
heuristic provides a framework to integrate heterogeneous
biological data sources within diffusion-based prioritization
methods that are based on the well known Random Walk with
restart algorithm (RWR). For the sake of exposition, in the
remainder we refer to the biological information associated
to a gene i (e.g., the set of its annotations) as the set of
its labels, denoted by labels(i). In this study, we only used
annotations from the Gene Ontology (GO in the remainder)
database to define labels, since at the moment it is one of the
most complete and best curated available datasets. We remark
however, that in principle any reliable information source on
gene biology can be integrated. BRW ranks genes according
to the following steps:
1) We compute the set of statistically significant annota-
tions of known disease genes, as for the BNR heuristic,
i.e., the enriched set
2) Rather than using the standard method1, we compute
individual teleporting probabilities for all nodes of the
PPI. In particular, the Biological Teleporting Probability
(BTP) of a node increases with the similarity between
its labels and the enriched set (details in Section III),
3) In a similar fashion, we weigh PPI network interactions
using node annotations and the enriched set. This results
in a modified random walk, namely the Biological
Random Walk (BRW), in which flow propagation is
biased toward genes that are functionally closer to those
forming the seed set.
4) Finally, we rank genes according to their Biological
Random Walk (BRW) score.
As the example in Figure 5 highlights, BRW not only
propagates flow to and from known disease genes, but also
involves a broader set of genes that are functionally related
to disease ones, though themselves not directly related to the
disease, at least to the best of our knowledge.
The results of Figure 2 suggest that BRW seems to leverage
both heterogeneous sources of biological information. In par-
1Whilst details are given in Section III, here we remind that in the standard
RWR approach [20], the probability of restarting the random walk from a
given seed node (disease gene) is the same for all seeds nodes, while it is 0
for other nodes of the PPI.
Fig. 2. Recall @k scores show how BRW performs better than other state-of-
the-art techniques. The recall is computed splitting the known disease genes
into two groups the seed nodes and the test nodes. The former are used
to run the algorithm, the latter are used has validation for the output of the
algorithms. The recall@k are the percentage on nodes of the test set discovered
in the first k position of the ranked lists, that are the output of the algorithm.
The splitting of the genes has been repeated 100 times, and the score is the
average of the experiment results. The BRW on average is able to find more
than 40% of the test nodes in the first 200 ranked genes.
ticular, it significantly outperforms RWR and DIAMOnD, but
it also achieves better recall than the BNR baseline across the
entire spectrum of the values k that we considered. We also
note that best results are achieved using a value 0.75 for the
restart probability. This intuitively means that best candidates
are mostly found in the vicinity of disease genes or genes that
are functionally related to them.
Beyond this internal validation of a more quantitative na-
ture, the paragraphs that follow report and discuss anecdotal
evidence, as to the potential biological interest of candidate
genes that are prioritized by our algorithm, but are not part of
the pool of known disease ones.
C. Functional analysis
Table I reports genes prioritized by our BRW algorithm
only. Therefore, we briefly discuss the relevance of some of
them to breast cancer, which is the most common malignancy
in women [5] and has the second highest incidence among
all types of cancer worldwide. Notably, the list in table X
contains two members of the erbB family which is composed
of closely related genes: erbB (her), erbB-2 (her-2, neu),
erbB-3 (her-3), and erbB-4 (her-4). This genes also encode
members of the epidermal growth factor (EGF) receptor family
of receptor tyrosine kinases. In particular, erbB-2 gene is a
proto-oncogene. In fact, overexpression of ErbB-2 leads to
transformation, tumorigenicity, and metastasis. These findings
support the implications of ErbB-2 as a major player in breast
cancer initiation and/or progression. Moreover, targeting of
ErbB-2 has proved to be effective for drug development [31].
Over expression of human epidermal growth factor receptor-2
(ErbB-2) has been found in 20-30% of breast cancer patients
and widely recognized as a reliable marker for metastatis
formation, drug resistance and high aggressiveness. Among
all of the drugs that target HerbB-2, trastuzumab, pertuzumab,
trastuzumab emtansine and lapatinib have been proven to be
effective in several clinical trials [32]. Another important gene
in our list is vegfa, a member of the Vascular Endothelial
Growth Factor (VEGF) family which plays an important role
in multiple physiologic and pathologic processes involving
endothelial cells. Several preclinical and clinical evidence
supports its relevance in breast cancer and, consequently,
numerous anti-VEGF drugs are now being under clinical
evaluation [30]. Interestingly, gene fgf9 of our list, plays a
role in many tumours, like breast cancer, that contain different
populations of cells which may show increased resistance to
anticancer drugs. There are now evidences of ”cancer stem-like
cells, which are important for survival and expansion of normal
stem cells. It has been reported that, in analogy to embryonic
mammary epithelial biology, estrogen signaling expands the
pool of functional breast cancer stem-like cells through a
paracrine Fgf/Fgfr/Tbx3 signaling pathway [15]. Moreover,
bmp4 gene in our list, encode the bone morphogenetic protein
4, which is a key regulator of cell proliferation and differentia-
tion. In breast cancer cells, bmp4 is able to reduce proliferation
and induce migration, invasion and metastatis formation in
vitro [3]. Last (but not least) we found gene p63 in our list
which is a transcription factor of the p53 gene family, widely
known to play a fundamental role in the development of all
the stratified squamous epithelia, including breast [12].
D. Robustness
We briefly mention here the robustness of our results to
the presence of possible noise in both interactome and anno-
tation data, finding that our framework is resilient to degree
preserving random shuffling on the graph [24] and it partially
decreases its performances when noising the annotation.
Fig. 3. PPI robustness analysis: Recall@k is measured after shuffling the
PPI interactions keeping node’s degree (continuous lines), and after shuffling
node’s annotations (dashed lines). As we can see all algorithms that use only
topological information fail in the case their input is noisy. BRW decrease
by 2/3 when shuffling the annotations: relying on two different sources, the
BRW is more resilient to noise.
III. MATERIALS AND METHODS
A. Datasets
1) PPI Network and Gene-Disease Associations: The ex-
periments discussed in Section II were conducted on the same
PPI network as [16] for the sake of comparison. In [16], the
authors only considered direct physical protein interactions
with reported experimental evidence. Several data sources
were used to derive this PPI network:
TABLE I
PRIORITIZED GENES FOUND ONLY BY BRW ALGORITHM AND NOT BY OTHER, USING AS INITIAL DISEASE GENES (seed nodes) ALL THE KNOWN GENES.
DETAILS ON PPI AND ALGORITHMS IN SECTION III.THE LEFT COLUMNS INDICATES THE PARAMETERS USED TO DEFINE THE ENRICHED SET.
Benjamini-Hochberg Correction P-value Annotations in Enriched set BRW prioritized genes
False 0.01 213 ERBB4, ERBB2, CDC42, TGFB1, FGF9, SIRT1
False 0.05 485 ERBB4, VEGFA, BMP4, TGFB1, BMP2, FGF9
True 0.01 80 ERBB4, TGFB1, BMP4, CDC42
True 0.05 318 ERBB2, PAK1, ERBB4, RAD50, XRCC2
Fig. 4. Recall @k scores on HIPPIE network [1].
• TRANSFAC [19]: this database lists regulatory interac-
tions derived from the presence of a transcription factor
binding site in the promoter region of a certain gene;
• IntAct [4], MINT [9], BioGRID [14] and HPRD [13]:
these databases list physical PPI interactions, typically
identified by low throughput experiments and manually
curated by experts;
• KEGG and BIGG [29]: sources used to find metabolic
enzyme-coupled interactions;
• CORUM [28]: this database lists mammalian protein
complexes as single molecular units that integrate multi-
ple gene products.
In addition, we considered the main connected component of
the network and we removed self-loops (i.e., edges describing
proteins’ self-interactions). The resulting graph consists of
13396 nodes and 138405 edges.
Disease genes association are the same as in [16]. Out of
a corpus of 70 diseases in which gene-disease associations
were retrieved from OMIM (Online Mendelian Inheritance
in Man [2]), in this work we focus on the Breast Cancer
phenotype, which involves 40 genes, refer to [16] for the
complete list. Experiments concerning other diseases will be
described and discussed in the journal version of the paper.
Though, repeating the same experiment on a different PPI,
HIPPIE [1], we obtain coherent results, see Figure 4.
2) Gene annotations: We retrieved gene biological infor-
mation from Gene Ontology Consortium: in this case, we
extracted annotations describing genes’ biological pro-
cesses. We downloaded the database in November 2018.
B. Algorithms
In the remainder, we use bold lowercase to denote vectors
and capital, non-bold letters to denote matrices. Given a vector
x, xi denotes its i-th entry. We use S to denote the subset of
PPI’s nodes associated to known disease genes, i.e., what we
call the seed set.
1) Random Walk with Restart: Random Walk with Restart
(RWR) [20] is a diffusion-based method, whose purpose is
identifying pathways that are topologically “close” to known
disease genes in the interactome. It was shown to outperform
other prioritization algorithms in many cases [25].
In a nutshell, this algorithm can be seen as performing mul-
tiple random walks over the PPI network, each starting from
a seed node associated to a known disease gene, iteratively
moving from one node to a random neighbour, thus simulating
the diffusion of the disease phenotype across the interactome.
More formally, the random walk with restart is defined as:
p(t+1) = (1− r)Wp(t) + rq. (1)
Here, W is the column-normalized adjacency matrix of the
graph and p(t) is a vector, whose i-th entry p(t)i is the
probability of the random walk being at node i at the end
of the t-th step. r ∈ (0, 1) is the restart probability. It is
the probability that the random walk is restarted from one
of the (disease-associated) seed nodes in the next step. Upon
a restart, the probability of restarting the random walk from
some seed node j is qj . This random walk corresponds to an
ergodic Markov chain [22] that admits a stationary distribution
(i.e., a fixed point) p. Nodes of the PPI are simply ranked by
considering the corresponding entries of p in descending order
of magnitude.
Following [20], in our implementation, the initial probability
vector q was uniform over the subset of seed nodes, i.e., qj =
1/|S| if j ∈ S, qj = 0 otherwise. We considered the following
values for the restart probability: r ∈ {0.25, 0.50, 0.75}.2
2) DIAMOnD Algorithm: The DIAMOnD (Disease Mod-
ule Detection) algorithm [16] relies on the hypothesis that
disease associated proteins do not necessarily reside within
locally dense communities. Instead, this algorithm identifies
connectivity significance (see paragraphs that follow for def-
inition) as the most predictive quantity. DIAMOnD exploits
this quantity to identify the full disease module starting from
a seed set of known disease proteins.
Consider a PPI network of N nodes, out of which a subset
S of seed proteins are associated with a particular disease.
Now, consider a protein with k links in the PPI network, out
of which ks to seed nodes. If seed proteins were distributed
uniformly at random in the network (null hypothesis), the
probability p(k, ks) that a protein with a total of k links has
2Note that [20] only considered the value 0.75.
exactly ks links to seed proteins (connectivity significance)
would be given by the hypergeometric distribution:
p(k, ks) =
(|S|
ks
) · (N−|S|k−ks )(
N
k
)
To evaluate whether a certain protein has more connections
to seed proteins than expected under this null hypothesis, the
DIAMOnD algorithm computes its connectivity p-value.
We followed the implementation of DIAMOnD. Note that
the set of p-values has to be recomputed in each iteration,
which makes the algorithm computationally demanding for
moderately large values of k. In our experiments, we consid-
ered values of k up to 200.
3) Biological Node Relevance: Building on the hypothesis
that genes involved in the same disease tend to be functionally
related and thus share similar biological information, we came
up with a very simple heuristic that ranks genes in the PPI
network according to the extent of their co-occurrence within
biological processes, what we call Biological Node Relevance
(BNR) henceforth. BNR is a simple (yet effective as we
shall see) baseline, which completely disregards information
implicit in the link structure of the PPI network.
Given a set S of seed nodes (known disease genes), the
algorithm first computes the set of annotations (see Section
III-A2) that are statistically significant for seed proteins, i.e.
the enriched set,3, by using Fishers exact test to this purpose,
with the P-value equal to 0.05 and the Benjamini-Hochberg
correction.
Next, given a list of N proteins (nodes of the PPI network),
BNR computes the score of each protein i, defined as the
intersection between the set of annotations in the enriched set
and the biological information of i, i.e.:
score(i) = |enriched set ∩ label(i)|,
where label(i) is the set of annotations of protein i.
Finally, BNR sorts proteins in descending order with respect
to their scores.
4) Biological Random Walk: The Biological Random Walk
(BRW) is a framework that exploits both biological (GO
annotations, KEGG pathways and miRNA) and topological
information (PPI network) to uncover potentially new disease
genes.
BRW is essentially a random walk with restart algorithm.
While the form of the governing equation is still (1), the
key differences are that both the transition matrix W and the
restart vector q now depend on available genes’ biological
information. For this reason, we call W and q respectively
Biological Transition matrix and Biological Teleporting
Probability vector in the remainder of this section.
Note that, differently from RWR, q and W also depend
on available biological information, so that the stationary
3We again remind that, while we consider gene annotations here, the same
approach can be adapted to different biological data.
distributions (and thus the rankings) produced RWR and
BRW generally differ.
Since the biological relevance of a node can’t be used
straight forward as a probability, we next describe how we
generate q and W , we explored several possibilities for
integrating and factoring in available biological information.
This implies the setting of several parameters. We used a grid
search to select the parameter configuration used in the final
round of experiments. For the sake of space, we refer to the
case of breast cancer as a disease and GO annotations as com-
plementary (with respect to the PPI) biological information.
The approach applies seamlessly to other data sources, such
as miRNA or KEGG (results will appear in the journal version
of the paper). In the remainder, labels(i) denotes the set of
annotations associated to a node i of the PPI network. As usual
S denotes the seed set of known disease nodes.
a) Biological Teleporting Probability (BTP) vector: The
i-th entry q of the BTP vector is defined as follows:
1) A measure of the overlap between labels(i) and
enriched set is computed. We call this the Node Rele-
vance NR(i). In this work we considered the following
definitions:
• NR(i) = |enriched set∩label(i)||enriched set| ,
• NR(i) = 1, whenever i ∈ S.
2) We let wi = min{t, f(NR(i))}, with f : R → [0, 1] a
suitable monotonically increasing function (Node Rel-
evance Function), and t ∈ [0, 1] used as a parameter
to weight the importance of the NR score overall. A
number of possible choices for f are presented in the
paragraphs that follow.
3) qi = wi/(
∑
i wi), for every node i of the PPI (normal-
ization).
In the experiments, we tested different choices for the Node
Scoring Function f . The first set consists of functions that
directly depend on NR(i):
• The power scoring function: f(NR(i), α) = NR(i)α,
with α > 04. When α = 1 we are directly using NR(i)
(default scoring function),
• The sigmoid scoring function outputs a value that
is smooth and bounded based on two parameters: the
steepness and translation parameters: f(NR(i), s, θ) =
1
1+e−((NR(i)−θ)·s)
We further considered node scoring functions that depend
on the rank of PPI nodes in descending order of their values of
NR(i) (i.e., higher NR(i), the lower the corresponding rank).
In more detail, let ri denote the rank of node i. We considered
the following, rank-dependent definitions for f :
• Linear: Given the rank ri of node i and the total
number N of nodes/proteins in the PPI, the linear ranking
function is defined as f(ri) = N−ri+1N .
• Inverse Sigmoid: In this case, for protein i we have:
f(ri) = 1− 11+e(−s·(ri−t)) .
4We considered α ∈ {0.5, 1, 1.5, 2}
Fig. 5. Biological Random Walk flow propagation: given the seed nodes (star nodes), the flow propagates to his neighbors. The BRW not only propagate
the flow around them but also teleports the flow to the target of the BTP nodes (blue arrows). So it discovers nodes that are biologically correlated to the
seed nodes (just through the BTP, left-lower test node) and those nodes that aren’t reached directly to the BTP but are close to many related nodes, the BRW
node (left-upper test node)
b) Biological Transition Matrix (BTM): Though other
choices are possible, for breast cancer, entry Wij of the
random walk’s transition matrix depends on the extent to
which nodes i and j of the PPI share common annotations (i.e.,
they are involved in common biological processes) that are also
significant for the disease. For breast cancer, we considered the
following Disease Specific Interaction function:
DSI(i, j) =
|enriched set ∩ label(i) ∩ label(j)|
|enriched set| .
Intuitively, DSI(i, j) will be higher, the more i and j share
annotations that are also statistically significant for the disease
under consideration.
Wij then depends on DSI(i, j) according to a scoring
function as follows:
Wij =
{
f(DSI(i, j)) if edge (i,j) belongs to PPI
0 otherwise
In the experiments tested different choices for the scoring
function f :
• Power scoring function: for each edge (i, j) we consider
f(DSI(i, j), α) = DSI(i, j)α, with α > 0.
• Summation scoring function: for each edge (i, j), we
let f(DSI(i, j), c) = DSI(i, j) + c.
• Sigmoid scoring function: for each edge (i, j), we have
f(DSI(i, j), s, t) = 1
1+e−((DSI(i,j)−θ)·s) , with θ and s
respectively the translation and steepness parameters.
C. Internal validation
a) Experimental setup: For each algorithm and for each
set of parameter values we considered, we considered the aver-
age value of Recall@k (defined below) over 100 independent
runs. In each run, the seed set of known disease genes was
randomly split into a training set, accounting for 70% of the
original seed set, and a test set, including the remaining 30%
of the genes.5
b) Performance measure: Intuitively, we are interested
in algorithms that identify new candidate genes that are
more likely to be of interest for further biological scrutiny.
Consistently, we measured performance using Recall. This is
the fraction of relevant items (in our case, known disease genes
in the test set) that are successfully retrieved by the algorithm.
Formally, in our scenario recall is defined as:
Recall =
|disease genes ∩ retrieved genes|
|disease genes| ,
where disease genes are known genes involved in the
phenotype and retrieved genes are genes prioritized by
the algorithm under consideration. Moreover, in order to
compare our approach with other baselines, we considered
Recall@k. In our framework, this is the value of recall when
retrieved genes the set of Top-K genes in the algorithm’s
ranking. We considered several values for k, namely, k ∈
{10, 20, 40, 50, 60, 70, 80, 90, 100, 150, 200}.
5For breast cancer, this amounts to 28 and 12 genes respectively.
c) Parameter setting: As for DIAMOnD, this is a
parameter-free algorithm. For RWR, we adopted the parameter
setting suggested in [20].
For BRW, as the previous paragraphs highlight, we used
a grid search to select the parameter configuration used in
the final round of experiments. In more detail, for each
considered parameter configuration, we took the average value
of Recall@k over 1000 independent runs of BRW. The
final configuration was the one achieving the best (average)
Recall@200 score, e.g. the ranking-inverse Sigmoid with
steepness 0.01 and translation 250 for the BTP construction
and the summation function for the DSI, with c = 1.
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